drugset
drugset / Trial / NCT01782261

Incretin Effect on the Immunological Phenotype

NCT01782261 ↗

Phase 2 Completed 15 enrolled Medical University of Graz
RandomizedParallel-groupOpen-labelTreatment

Summary

Assessment of the effect of incretin based therapies (Liraglutide and Saxagliptin) on immune cells in healthy subjects and patients with type 1 diabetes

Timeline

Start
2012-02
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.2 mg Subcutaneous
Comparator SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral

Indications

type 1 diabetes mellitus